Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation

BMC Medical Genomics

Volumn 6, Issue SUPPL. 3, 2013, Pages

  Huang, Yu Fen ^a   Yeh, Hsiang Yuan ^a   Soo, Von Wun ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DROSTANOLONE; FLUOXYMESTERONE; GLYCOGEN SYNTHASE KINASE 3; LINOLEIC ACID; OXANDROLONE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CHEMICAL STRUCTURE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG RESPONSE; ENZYME REGULATION; FAT INTAKE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS; PHENOTYPE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84887924060     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-S3-S4     Document Type: Conference Paper

References (78)

1. The human disease network. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL, Proc Natl Acad Sci USA 2007 104 21 8685 8690 10.1073/pnas. 0701361104 17502601 (Pubitemid 47175372)
2. New drug development in the United States from 1963 to 1999. Dimasi JA, Clin Pharmacol Ther 2001 69 286 96 10.1067/mcp.2001.115132 11371996 (Pubitemid 32477069)
3. Estimating the cost of new drug development: Is it really 802 million dollars? Adams CP, Brantner VV, Health Aff (Millwood) 2006 25 402 8 16522582
4. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL, Nat Rev Drug Discov. 2010 9 3 203 14 20168317
5. R&D Costs and Returns by Therapeutic Category. DiMasi J, Hansen R, Grabowski H, Drug Information Journal 2004 38 211 223 (Pubitemid 39121144)
6. The Comparative toxicogenomics database (CTD): a resource for comparative toxicological studies. Mattingly CJ, Rosenstein MC, Colby GT, Forrest JN, Boyer JL, J Exp Zool A Comp Exp Biol 2006 305 689 692 16902965 (Pubitemid 44358296)
7. Prediction of Human Genes and Diseases Targeted by Xenobiotics Using Predictive Toxicogenomics-Derived Models (PTDMs). Cheng F, Li W, Zhou Y, Lee PW, Tang Y, Mol BioSyst 2013
8. PharmGKB: an integrated resource of pharmacogenomic data and knowledge. Gong L, Owen RP, Gor W, Altman RB, Klein TE, Curr Protoc Bioinformatics 2008 nit 14.7 Chapter 14 18819074
9. PROMISCUOUS: a database for network-based drugrepositioning. von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R, Nucleic Acids Res 2011 39 1060 6 10.1093/nar/gkq1037 21071407
10. The Connectivity Map: a new tool for biomedical research. Lamb J, Nat Rev Cancer 2007 7 54 60 10.1038/nrc2044 17186018 (Pubitemid 46020847)
11. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR, Science 2006 313 1929 1935 10.1126/science.1132939 17008526 (Pubitemid 44497995)
12. Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. Li J, Zhu X, Chen JY, PLoS Comput Biol 2009 5 1000450 10.1371/journal.pcbi.1000450 19649302
13. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Chiang AP, Butte AJ, Clin Pharmacol Ther 2009 86 507 510 10.1038/clpt.2009.103 19571805
14. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Gottlieb A, Stein GY, Ruppin E, Sharana R, Mol Syst Biol 2011 7 496 21654673
15. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, Butte AJ, PLoS Comput Biol 2010 6 1000662 10.1371/journal.pcbi.1000662 20140234
16. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. Daminelli S, Haupt VJ, Reimann M, Schroeder M, Integr Biol (Camb) 2012 4 7 778 88 10.1039/c2ib00154c 22538435
17. A pathway profile-based method for drug repositioning. Ye H, Yang LL, Cao ZW, Tang KL, Li YX, Chinese Science Bulletin 2012 57 2106 2112 10.1007/s11434-012-4982-9
18. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Hamosh A, Scott AF, Amberger J, Bocchini C, Valle D, McKusick VA, Nucleic Acids Res 2002 30 52 55 10.1093/nar/30.1.52 11752252 (Pubitemid 34679502)
19. A text-mining analysis of the human phenome. van Driel MA, Bruggeman J, Vriend G, Brunner HG, Leunissen JA, Eur J Hum Genet 2006 14 535 542 10.1038/sj.ejhg.5201585 16493445
20. PRINCIPLE: A tool for associating genes with diseases via network propagation. Gottlieb A, Magger O, Berman I, Ruppin E, Bioinformatics 2011 27 3325 6 10.1093/bioinformatics/btr584 22016407
21. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M, Nucleic Acids Res 2008 36 901 D906 18048412
22. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. Weininger D, J Chem Inf Comput Sci 1988 28 31 36 10.1021/ci00057a005 (Pubitemid 18574254)
23. Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. Steinbeck C, Hoppe C, Kuhn S, Floris M, Guha R, Willighagen EL, Curr Pharm Des 2006 12 2111 2120 10.2174/138161206777585274 16796559 (Pubitemid 43891407)
24. Tanimoto T, Internal report: IBM Technical Report Series 1957
25. APID: Agile Protein Interaction Data Analyzer. Prieto C, De Las Rivas J, Nucleic Acids Research 2006 34 298 302 10.1093/nar/gkl128 16845013 (Pubitemid 44529782)
26. Walking the Interactome for Prioritization of Candidate Disease Genes. Kohler S, Bauer S, Horn D, Robinson PN, Am J Hum Genet 2008 82 4 949 958 10.1016/j.ajhg.2008.02.013 18371930
27. Co-ranking authors and documents in a heterogeneous network. Zhou D, Orshanskiy SA, Zha H, Giles CL, In ICDM 2007 739 744
28. A Heterogeneous Label Propagation Algorithm for Disease Gene Discovery. Hwang TH, Kuang R, Proc of SIAM International Conference on Data Mining (SDM) 2010 583 594
29. Link Fusion: A Unified Link Analysis Framework for Multi-Type Interrelated Data Objects. Xi W, Zhang B, Chen Z, Lu Y, Yan S, Ma WY, Fox EA, World Wide Web Conference Series-WWW 2004 319 327 (Pubitemid 40752766)
30. Citation influence for journal aggregates of scientific publications: Theory, with application to the literature of physics. Pinski G, Narin N, Information Process and Management 1976 12 297 312 10.1016/0306-4573(76)90048-0
31. Learning with local and global consistency. Zhou D, Weston J, Gretton A, Bousquet O, Scholkopf B, In NIPS 2004 16 321 328
32. Use of Data-Biased Random Walks on Graphs for the Retrieval of Context-Specific Networks from Genomic Data. Komurov K, White MA, Ram PT, PLoS Comput Biol 2010 6 8 1000889 10.1371/journal.pcbi.1000889 20808879
33. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR, Proc Natl Acad Sci U S A 2004 101 3 811 816 10.1073/pnas.0304146101 14711987 (Pubitemid 38121040)
34. The stanford microarray database. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight SS, Kaloper M, Weng S, Jin H, Ball CA, Eisen MB, Spellman PT, Brown PO, Botstein D, Cherry JM, Nucleic Acids Research 2001 29 152 155 10.1093/nar/29.1.152 11125075 (Pubitemid 32054432)
35. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC, PLoS One 2009 4 5 5645 10.1371/journal.pone.0005645 19461970
36. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Hong Y, Ho KS, Eu KW, Cheah PY, Clin Cancer Res 2007 13 4 1107 14 10.1158/1078-0432.CCR- 06-1633 17317818 (Pubitemid 46424049)
37. Network-based inferring drug-disease associations from chemical, genomic and phenotype data. Huang YF, Yeh HY, Soo VW, Bioinformatics and Biomedicine (BIBM), 2012 IEEE International Conference on: 4-7 October 2012 2012 1 6 10.1109/BIBM.2012.6392658
38. Human Disease-Drug Network Based on Genomic Expression Profiles. Hu G, Agarwal P, PLoS ONE 2009 4 8 6536 10.1371/journal.pone.0006536 19657382
39. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, Zhou W, Huang J, Tang Y, PLoS Comput Biol. 2012 8 5 1002503 10.1371/journal.pcbi.1002503 22589709
40. Combinatorial preferences affect molecular similarity/diversity calculations using binary fingerprints and Tanimoto coefficients. Godden JW, Xue L, Bajorath J, J Chem Inf Comput Sci 2000 40 163 166 10.1021/ci990316u 10661563
41. Do structurally similar molecules have similar biological activity? Martin YC, Jacson RM, J Med Chem 2002 45 4350 4358 10.1021/jm020155c 12213076 (Pubitemid 35025581)
42. Drug-target network. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, Nat Biotechnol 2007 25 10 1119 26 10.1038/nbt1338 17921997 (Pubitemid 47538114)
43. STITCH 3: zooming in on protein-chemical interactions. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, Bork P, Nucleic Acids Res. 2012 40 Database 876 80 22075997
44. Extraction of gene-disease relations from Medline using domain dictionaries and machine learning. Chun HW, Tsuruoka Y, Kim JD, Shiba R, Nagata N, Hishiki T, Tsujii J, Pac Symp Biocomput 2006 4 15 17094223
45. Predicting Chemical Toxicity Effects Based on Chemical-Chemical Interactions. Chen L, Lu J, Zhang J, Feng KR, Zheng MY, Cai YD, PLoS One. 2013 8 2 56517 10.1371/journal.pone.0056517 23457578
46. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K, Am J Physiol Endocrinol Metab 2004 286 6 927 31 10.1152/ajpendo.00443.2003 14761877 (Pubitemid 38668814)
47. Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate. Giorgi E, Shirley I, Grant J, Stewart J, Biochem J 1973 132 3 465 74 4125095
48. Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. Jones WG, Fosså SD, Bono AV, Croles JJ, Stoter G, Pauw MD, Sylvester R, World Journal of Urology 1986 4 3 182 185 10.1007/BF00327017 (Pubitemid 17042157)
49. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00031889
50. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, PNAS 2005 102 43 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
51. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA, Genome Biology 2007 8 9 183 10.1186/gb-2007-8-9-r183 17784955 (Pubitemid 351895482)
52. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA, Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators, British Association of Urological Surgeons Section of Oncology, Am J Hum Genet 2003 72 1 12 10.1086/345310 12474142 (Pubitemid 36056838)
53. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Hucl T, Gallmeier E, Physiol Res. 2011 60 3 453 65 21401292
54. Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders. Mattson MP, Duan W, Chan SL, Camandola S, J Mol Neurosci 1999 3 1-2 17 30 10691289 (Pubitemid 30101997)
55. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM, Mol Cancer Ther 2008 7 2884 2893 10.1158/1535-7163.MCT- 08-0438 18790769
56. PAR-4 as a possible new target for pancreatic cancer therapy. Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM, Expert Opin Ther Targetsm 2010 14 6 611 20 10.1517/14728222.2010.487066 20426700
57. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. Larsson SC, Orsini N, Wolk A, JAMA 2010 303 11 1077 83 10.1001/jama.2010.263 20233826
58. Assessment of risk associated with specific fatty acids and colorectal cancer among French-Canadians in Montreal: a case-control study. Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P, Int J Epidemiol. 2003 32 2 200 9 10.1093/ije/dyg048 12714537 (Pubitemid 36622263)
59. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N, Yagi K, Life Sci 2002 70 19 2253 69 10.1016/S0024-3205(01)01545-4 12005185 (Pubitemid 34251296)
60. Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Lee HR, Cheong HJ, Kim SJ, Lee NS, Park HS, Won JH, Oncol Rep 2008 20 1 41 7 18575716
61. Polyamines and colon cancer. Milovic V, Turchanowa L, Biochem Soc Trans 2003 31 2 381 3 10.1042/BST0310381 12653643 (Pubitemid 36520681)
62. The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Allen WL, McLean EG, Boyer J, McCulla A, Wilson PM, Coyle V, Longley DB, Casero RA Jr, Johnston PG, Mol Cancer Ther 2007 6 1 128 37 10.1158/1535-7163.MCT-06-0303 17237273 (Pubitemid 46206675)
63. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H, Clin Cancer Res 2009 15 19 6208 16 10.1158/1078-0432.CCR-09-0592 19789310
64. De novo synthesis of arginine and ornithine from citrulline in human colon carcinoma cells: metabolic fate of L-ornithine. Selamnia M, Robert V, Mayeur C, Delpal S, Blachier F, Biochim Biophys Acta 1998 1425 1 93 102 10.1016/S0304-4165(98)00056-7 9813260 (Pubitemid 28479716)
65. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A, Clin Cancer Res 2005 11 5526 5533 10.1158/1078-0432.CCR-05-0081 16061869 (Pubitemid 41060829)
66. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ, J Clin Oncol 2008 26 2320 2326 10.1200/JCO.2007.14.0152 18467723
67. Bacteria and cancer: cause, coincidence or cure? A review. Mager DL, J Transl Med 2006 4 14 10.1186/1479-5876-4-14 16566840
68. Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. Yoshioka T, Morimoto Y, Iwagaki H, Itoh H, Saito S, Kobayashi N, Yagi T, Tanaka N, J Int Med Res 2001 29 5 409 20 10.1177/147323000102900505 11725828 (Pubitemid 33061660)
69. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER, J Biol Chem 2002 277 24 21657 65 10.1074/jbc.M200139200 11940574 (Pubitemid 34952316)
70. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T, Biochem Biophys Res Commun. 2005 334 4 1365 73 10.1016/j.bbrc.2005.07.041 16043125 (Pubitemid 41074725)
71. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q, Cancer Res 2005 65 19 9012 20 10.1158/0008-5472.CAN-05-1226 16204075 (Pubitemid 41377393)
72. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, Ferri LE, Cancer Res 2011 71 5 1989 98 10.1158/0008-5472.CAN-10-2833 21363926
73. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Doan HQ, Bowen KA, Jackson LA, Evers BM, Anticancer Res. 2009 29 7 2473 8 19596916
74. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Slattery ML, Herrick JS, Bondurant KL, Wolff RK, Int J Cancer 2012 130 12 2974 80 10.1002/ijc.26314 21792899
75. S100A8/A9 activate key genes and pathways in colon tumor progression. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G, Mol Cancer Res 2011 9 2 133 48 10.1158/1541-7786.MCR-10-0394 21228116
76. The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells. Untersmayr E, Bises G, Starkl P, Bevins CL, Scheiner O, Boltz-Nitulescu G, Wrba F, Jensen-Jarolim E, PLoS One 2010 5 9023 10.1371/journal.pone.0009023 20126404
77. The p75 neurotrophin receptor is a central regulator of glioma invasion. Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, Senger DL, PLoS Biol 2007 5 8 212 10.1371/journal.pbio.0050212 17696644 (Pubitemid 47328276)
78. Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Choi HJ, Park KJ, Kim HJ, Roh MS, Anticancer Res. 2010 30 10 4163 8 21036736